A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
|
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 35 条
  • [1] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
  • [2] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    A Dewdney
    D Cunningham
    Y Barbachano
    I Chau
    British Journal of Cancer, 2012, 106 : 1718 - 1721
  • [3] A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
    Wong, R.
    Cunningham, D.
    Barbachano, Y.
    Saffery, C.
    Valle, J.
    Hickish, T.
    Mudan, S.
    Brown, G.
    Khan, A.
    Wotherspoon, A.
    Strimpakos, A. S.
    Thomas, J.
    Compton, S.
    Chua, Y. J.
    Chau, I.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2042 - 2048
  • [4] A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer
    M. Michael
    J. Zalcberg
    P. Gibbs
    L. Lipton
    M. Gouillou
    M. Jefford
    G. McArthur
    M. Copeman
    K. Lynch
    N. C. Tebbutt
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 321 - 330
  • [5] Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
    Dewdney, A.
    Cunningham, D.
    Barbachano, Y.
    Chau, I.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1718 - 1721
  • [6] Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
    Gruenberger, T.
    Bridgewater, J.
    Chau, I.
    Garcia Alfonso, P.
    Rivoire, M.
    Mudan, S.
    Lasserre, S.
    Hermann, F.
    Waterkamp, D.
    Adam, R.
    ANNALS OF ONCOLOGY, 2015, 26 (04) : 702 - 708
  • [7] Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
    Bekaii-Saab, Tanios S.
    Balser, Sigrid
    Lohmann, Ragna
    Daoud, Hasan
    Liedert, Bernd
    Schliephake, Dorothee
    COLORECTAL CANCER, 2022, 11 (01)
  • [8] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
    Nishina, Tomohiro
    Takano, Yoshinao
    Denda, Tadamichi
    Yasui, Hisateru
    Takeda, Koji
    Ura, Takashi
    Esaki, Taito
    Okuyama, Yusuke
    Kondo, Ken
    Takahashi, Yasuo
    Sugiyama, Yasuyuki
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
  • [9] Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
    Baldin, Pamela
    Carrasco, Javier
    Beniuga, Gabriela
    Jouret-Mourin, Anne
    Demolin, Gauthier
    Roland, Sandrine
    D'Hondt, Lionel
    Vergauwe, Philippe
    Van Daele, Daniel
    Mailleux, Marie
    Sinapi, Isabelle
    De Cuyper, Astrid
    Bletard, Noella
    Massart, Brigitte
    Delos, Monique
    Castella, Marie-Laure
    van Maanen, Aline
    Van den Eynde, Marc
    CANCERS, 2022, 14 (05)
  • [10] Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study
    Takahashi, Takao
    Shibata, Yoshihisa
    Tojima, Yuichiro
    Tsuboi, Kenji
    Sakamoto, Eiji
    Kunieda, Katsuyuki
    Matsuoka, Hiroshi
    Suzumura, Kazuyoshi
    Sato, Mikinori
    Naganuma, Tatsushi
    Sakamoto, Junichi
    Morita, Satoshi
    Kondo, Ken
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (02) : 335 - 342
1234